Brain Region–Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

References

1. 1.↵
   1. Moser HW

   2. ,Boustany RM

   . Batten disease or neuronal ceroid lipofuscinosis. In: Moser HW, ed. Handbook of Clinical Neurology. Vol 22. New York: Elsevier; 1996:671–700
2. 2.↵
   2. Haltia M

   . The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 2006;1762:850–56 doi:10.1016/j.bbadis.2006.06.010 pmid:16908122

   CrossRefPubMed
3. 3.↵
   2. Kohlschütter A,
   3. Schulz A

   . Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev 2009;31:499–502 doi:10.1016/j.braindev.2008.12.008 pmid:19195801

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Jalanko A,
   3. Braulke T

   . Neuronal ceroid lipofuscinoses. Biochim Biophys Acta 2009;1793:697–709 doi:10.1016/j.bbamcr.2008.11.004 pmid:19084560

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Mole SE,
   3. Cotman SL

   . Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta 2015;1852:2237–41 doi:10.1016/j.bbadis.2015.05.011 pmid:26026925

   CrossRefPubMed
6. 6.↵
   2. Mole SE

   . NCL mutation and patient database. http://www.ucl.ac.uk/ncl/mutation.shtml. Accessed August 6, 2015.
7. 7.↵
   2. Schulz A,
   3. Kohlschütter A,
   4. Mink J, et al

   . NCL diseases: clinical perspectives. Biochim Biophys Acta 2013;1832:1801–06 doi:10.1016/j.bbadis.2013.04.008 pmid:23602993

   CrossRefPubMed
8. 8.↵
   1. Mole S,
   2. Williams RE,
   3. Goebel HH,
   4. Mole S

   2. Chang M,
   3. Cooper BL,
   4. Davidson OP

   . CLN2. In: Mole S, Williams RE, Goebel HH, Mole S, eds. The Neuronal Ceroid Lipofuscinoses (Batten Disease). 2nd ed. Oxford: Oxford University Press; 2011:80–102
9. 9.↵
   2. Vines DJ,
   3. Warburton MJ

   . Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett 1999;443:131–35 doi:10.1016/S0014-5793(98)01683-4 pmid:9989590

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Lin L,
    3. Sohar I,
    4. Lackland H, et al

    . The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J Biol Chem 2001;276:2249–55 doi:10.1074/jbc.M008562200 pmid:11054422

    Abstract/FREE Full Text
11. 11.↵
    2. Glees P,
    3. Hasan M

    . Lipofuscin in neuronal aging and diseases. Norm Pathol Anat (Stuttgart) 1976;32:1–68
12. 12.↵
    2. Mitchison HM,
    3. Lim MJ,
    4. Cooper JD

    . Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol 2004;14:86–96 doi:10.1111/j.1750-3639.2004.tb00502.x pmid:14997941

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Birch DG

    , Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: an overview. Mol Genet Metab 1999;66:356–66 doi:10.1006/mgme.1999.2829 pmid:10191129

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Wisniewski KE,
    3. Kida E,
    4. Golabek AA, et al

    . Neuronal ceroid lipofuscinoses: classification and diagnosis. Adv Genet 2001;45:1–34 doi:10.1016/S0065-2660(01)45002-4 pmid:11332767

    CrossRefPubMed
15. 15.↵
    2. Worgall S,
    3. Kekatpure MV,
    4. Heier L, et al

    . Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurol 2007;69:521–35 doi:10.1212/01.wnl.0000267885.47092.40 pmid:17679671

    Abstract/FREE Full Text
16. 16.↵
    NINDS. Batten Disease Fact Sheet. NIH Publication No. 11-2790. http://www.ninds.nih.gov/disorders/batten/detail_batten.htm. Accessed September 1, 2015.
17. 17.↵
    2. Dyke JP,
    3. Sondhi D,
    4. Voss HU, et al

    . Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am J Neuroradiol 2013;34:884–89 doi:10.3174/ajnr.A3297 pmid:23042927

    Abstract/FREE Full Text
18. 18.↵
    2. Brodmann K

    . Vergleichende Lokalisationslehre der Grosshirnrinde. Leipzig: J.A. Barth; 1909
19. 19.↵
    2. Dale AM,
    3. Fischl B,
    4. Sereno MI

    . Cortical surface-based analysis, I: segmentation and surface reconstruction. Neuroimage 1999;9:179–94 doi:10.1006/nimg.1998.0395 pmid:9931268

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Clarkson MJ,
    3. Cardoso MJ,
    4. Ridgway GR, et al

    . A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856–65 doi:10.1016/j.neuroimage.2011.05.053 pmid:21640841

    CrossRefPubMed
21. 21.↵
    2. Tillema JM,
    3. Marloes GM,
    4. Powels PJ, et al

    . Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy. Ann Clin Trans Neurol 2015;2:932–40 doi:10.1002/acn3.232 pmid:26401514

    CrossRefPubMed
22. 22.↵
    2. Pagonabarraga J,
    3. Corcuera-Solano I,
    4. Vives-Gilabert Y, et al

    . Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. PLoS One 2013;8:e54980 doi:10.1371/journal.pone.0054980 pmid:23359616

    CrossRefPubMed
23. 23.↵
    2. Rohrer JD,
    3. Warren JD,
    4. Modat M, et al

    . Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009;72:1562–69 doi:10.1212/WNL.0b013e3181a4124e pmid:19414722

    Abstract/FREE Full Text
24. 24.↵
    2. Lebedeva A,
    3. Westman E,
    4. Lebedev AV, et al

    ; Alzheimer's Disease Neuroimaging Initiative. Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. Neurol Neurosurg Psychiatry 2014;85:930–35 doi:10.1136/jnnp-2013-307110 pmid:24421287

    Abstract/FREE Full Text
25. 25.↵
    2. Fischl B,
    3. Dale AM

    . Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000;97:11050–55 pmid:10984517

    Abstract/FREE Full Text
26. 26.↵
    2. Desikan RS,
    3. Ségonne F,
    4. Fischl B, et al

    . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–80 pmid:16530430

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Diggle P,
    3. Heagerty P,
    4. Liang KY, et al

    . Analysis of Longitudinal Data. New York: Oxford University Press; 2002
28. 28.↵
    2. Holm S

    . A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979;6:65–70

    CrossRefWeb of Science
29. 29.↵
    2. Orlin A,
    3. Sondhi D,
    4. Witmer MT, et al

    . Spectrum of ocular manifestations in CLN2-associated Batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS One 2013;8:e73128 doi:10.1371/journal.pone.0073128 pmid:24015292

    CrossRefPubMed
30. 30.↵
    2. Wierenga LM,
    3. Langen M,
    4. Oranje B, et al

    . Unique developmental trajectories of cortical thickness and surface area. Neuroimage 2014;87:120–26 doi:10.1016/j.neuroimage.2013.11.010 pmid:24246495

    CrossRefPubMed
31. 31.↵
    2. Muftuler LT,
    3. Davis EP,
    4. Buss C, et al

    . Cortical and subcortical changes in typically developing preadolescent children. Brain Res 2011;1399:15–24 doi:10.1016/j.brainres.2011.05.018 pmid:21640983

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Giedd JN,
    3. Blumenthal J,
    4. Jeffries NO, et al

    . Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999;2:861–63 pmid:10491603

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Dickerson BC,
    3. Fenstermacher E,
    4. Salat DH, et al

    . Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. Neuroimage 2008;39:10–18 pmid:17942325

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Han X,
    3. Jovicich J,
    4. Salat D, et al

    . Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;32:180–94 pmid:16651008

    CrossRefPubMedWeb of Science